Search research articles
Contact Us
Filters
Showing results (81-90 of 168) with videos related to
Page
of 17
Sort By:
Journal of Clinical Psychopharmacology
|
April 22, 2011
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial
Corrado Barbui, Simone Accordini, Michela Nosè, et al.
JMIR Mental Health
|
November 4, 2022
Development of the First Episode Digital Monitoring mHealth Intervention for People With Early Psychosis: Qualitative Interview Study With Clinicians
Ana Stefancic, R Tyler Rogers, Sarah Styke, et al.
Plos One
|
September 30, 2020
Mortality risk of antipsychotic augmentation for adult depression
Tobias Gerhard, T Scott Stroup, Christoph U Correll, et al.
Schizophrenia Research
|
August 4, 2006
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
Henry A Nasrallah, Jonathan M Meyer, Donald C Goff, et al.
Schizophrenia Research
|
April 10, 2020
A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia
Paul A Nakonezny, Janet C Lindow, T Scott Stroup, et al.
General Hospital Psychiatry
|
January 13, 2009
The impact of obesity on health care costs among persons with schizophrenia
Lydia A Chwastiak, Robert A Rosenheck, Joseph P McEvoy, et al.
Focus (American Psychiatric Publishing)
|
September 6, 2021
Mortality Risk of Antipsychotic Augmentation for Adult Depression
Tobias Gerhard, T Scott Stroup, Christoph U Correll, et al.
The Journal of Clinical Psychiatry
|
April 7, 2012
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial
Nancy H Covell, Joseph P McEvoy, Nina R Schooler, et al.
Biological Psychiatry
|
December 13, 2006
NCAM1 and neurocognition in schizophrenia
Patrick F Sullivan, Richard S E Keefe, Leslie A Lange, et al.
Schizophrenia Research
|
September 27, 2005
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial
Scott Stroup, Paul Appelbaum, Marvin Swartz, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 168) with videos related to
Sort By:
Page
of 17
Journal of Clinical Psychopharmacology
|
April 22, 2011
Aripiprazole versus haloperidol in combination with clozapine for treatment-resistant schizophrenia in routine clinical care: a randomized, controlled trial
Corrado Barbui, Simone Accordini, Michela Nosè, et al.
JMIR Mental Health
|
November 4, 2022
Development of the First Episode Digital Monitoring mHealth Intervention for People With Early Psychosis: Qualitative Interview Study With Clinicians
Ana Stefancic, R Tyler Rogers, Sarah Styke, et al.
Plos One
|
September 30, 2020
Mortality risk of antipsychotic augmentation for adult depression
Tobias Gerhard, T Scott Stroup, Christoph U Correll, et al.
Schizophrenia Research
|
August 4, 2006
Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline
Henry A Nasrallah, Jonathan M Meyer, Donald C Goff, et al.
Schizophrenia Research
|
April 10, 2020
A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia
Paul A Nakonezny, Janet C Lindow, T Scott Stroup, et al.
General Hospital Psychiatry
|
January 13, 2009
The impact of obesity on health care costs among persons with schizophrenia
Lydia A Chwastiak, Robert A Rosenheck, Joseph P McEvoy, et al.
Focus (American Psychiatric Publishing)
|
September 6, 2021
Mortality Risk of Antipsychotic Augmentation for Adult Depression
Tobias Gerhard, T Scott Stroup, Christoph U Correll, et al.
The Journal of Clinical Psychiatry
|
April 7, 2012
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial
Nancy H Covell, Joseph P McEvoy, Nina R Schooler, et al.
Biological Psychiatry
|
December 13, 2006
NCAM1 and neurocognition in schizophrenia
Patrick F Sullivan, Richard S E Keefe, Leslie A Lange, et al.
Schizophrenia Research
|
September 27, 2005
Decision-making capacity for research participation among individuals in the CATIE schizophrenia trial
Scott Stroup, Paul Appelbaum, Marvin Swartz, et al.
Page
of 17